Mirtazapina Flas Ratiopharm (Mirtazapine)

Mirtazapine works by blocking presynaptic alpha‑2 adrenergic receptors, which increases norepinephrine release, and by antagonizing specific serotonin receptors (5‑HT2 and 5‑HT3). It also blocks histamine H1 receptors, leading to enhanced serotonergic and noradrenergic neurotransmission and a sedative effect that helps improve mood.

The dose of Mirtazapina Flas Ratiopharm is individualized. A qualified prescriber determines the appropriate starting dose, titration schedule, and maintenance dose based on the patient’s clinical condition, response, and tolerability.

Safety data for mirtazapine in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any potential risk to the fetus or infant, and decisions should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mirtazapine belongs to the NaSSA class, which differs from SSRIs and SNRIs by its dual antagonism of alpha‑2 adrenergic and specific serotonin receptors. This mechanism often results in pronounced sedative and appetite‑stimulating effects, making it useful for patients with insomnia or weight loss, whereas SSRIs tend to be more activating.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original packaging to protect from moisture and light. Do not store in a bathroom or near heat sources, and keep out of reach of children.

Mirtazapina Flas Ratiopharm is taken orally, usually as a tablet. It can be swallowed with or without food, and patients are advised to follow the prescriber’s instructions regarding timing and any dose adjustments.

Serious risks include agranulocytosis (a severe drop in white blood cells), hepatotoxicity (liver injury), and the emergence of suicidal thoughts, particularly during the initial weeks of therapy. Any signs of infection, jaundice, or worsening mood should prompt immediate medical evaluation.

Patients with known hypersensitivity to mirtazapine or any component of the formulation should avoid the product. It is also contraindicated in individuals currently taking monoamine oxidase inhibitors (MAOIs) or those who have used an MAOI within the past 14 days.